Trial of Pimavanserin in Dementia-Related Psychosis
New England Journal of Medicine2021Vol. 385(4), pp. 309–319
Citations Over TimeTop 1% of 2021 papers
Pierre N. Tariot, Jeffrey L. Cummings, Maria Soto‐Martin, Clive Ballard, Deniz Erten‐Lyons, David L. Sultzer, Davangere P. Devanand, Daniel Weintraub, Bradley McEvoy, James M. Youakim, Srdjan Stankovic, Erin P. Foff
Abstract
In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation. Longer and larger trials are required to determine the effects of pimavanserin in dementia-related psychosis. (Funded by Acadia Pharmaceuticals; HARMONY ClinicalTrials.gov number, NCT03325556.).
Related Papers
- → Clinical Characteristics of Patients With Schizophrenia Who Successfully Discontinued Antipsychotics(2018)16 cited
- Current and future applications of SPECT in clinical psychiatry.(1992)
- [Discontinuation of neuroleptics in chronic schizophrenics. I. Summary of the literature].(1979)
- Types Research of Discontinuation of a Crime(2007)